Imcyse technology represents a totally new paradigm. It involves peptide vaccines that specifically block the immune responses causing the diseases.
Imcyse technology platform has shown its capacity to eliminate autoreactive target specific lymphocytes without affecting any of the other functions of the immune system. Imcyse therapeutic vaccines comprise target antigenic peptides together with a specific thioredox motif (a few amino-acids) and aluminum salts as adjuvant. Antigenic peptides are HLA-Class II and/or NKT epitopes of targeted antigens.
Vaccination with a synthetic peptide containing an autoantigen-derived class II-restricted epitope and a thioredox motif elicits antigen-specific cytolytic CD4 T cells eliminating antigen-presenting cells (APC) with which a synapse is formed, as well as autoantigen-specific bystander T cells activated on the surface of the same APC.
Multiple proofs of concept have been established in autoimmune diseases, including type 1 diabetes and multiple sclerosis, as well as in graft rejection and in allergic asthma.